CAR-T cell therapy for the treatment of adult high-grade gliomas

Sangwoo Park; Marcela V Maus; Bryan D Choi

doi:10.1038/s41698-024-00753-0

CAR-T cell therapy for the treatment of adult high-grade gliomas

NPJ Precis Oncol. 2024 Dec 19;8(1):279. doi: 10.1038/s41698-024-00753-0.

Authors

Sangwoo Park¹, Marcela V Maus¹, Bryan D Choi^{2

3}

Affiliations

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
² Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. bchoi@mgh.harvard.edu.
³ Brain Tumor Immunotherapy Lab, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. bchoi@mgh.harvard.edu.

Abstract

Treatment for malignant primary brain tumors, including glioblastoma, remains a significant challenge despite advances in therapy. CAR-T cell immunotherapy represents a promising alternative to conventional treatments. This review discusses the landscape of clinical trials for CAR-T cell therapy targeting brain tumors, highlighting key advancements like novel target antigens and combinatorial strategies designed to address tumor heterogeneity and immunosuppression, with the goal of improving outcomes for patients with these aggressive cancers.

Publication types

Review

Grants and funding

DRG-2529-24/Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation)